Lídia Einsfeld

Lídia Einsfeld

Auto-generated profile, based on publicly available information

Lídia Einsfeld

Universidade de Brasília

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
RARafaela Dall Agnol
Rafaela Dall Agnol
MSMaitê T dos Santos
Maitê T dos Santos
Mariana MichalowskiMariana Michalowski
Mariana Michalowski
LELídia Einsfeld
Lídia Einsfeld
Background: In oncology, pharmacists contribute to safety and effectiveness of drug treatment, identifying, preventing and forwarding solutions to drug-related problems (DRPs). However, it is still necessary to elucidate the profile of drug-related problems in pediatric cancer treatment to contribute to guide clinical pharmacy activities. Methods: A retrospective cross-sectional study was conducted. Records on Excel® spreadsheets of 2 years of pharmaceutical assistance were analyzed regarding the prescriptions of chemotherapy for hospitalized patients aged 0–19 years. Data on age, sex, cancer diagnosis, protocol and drugs prescribed were collected. Causes and types of DRPs and pharmacists’ interventions as their rate of acceptance were measured according to PCNE V 9.0. Results: Drug-related problems were identified for 84 patients, in 5.3% of analyzed prescriptions. Leukemias, patients aged 0–4 years and male sex were associated with higher rates of drug-related problems. The BFM 2009 protocol for acute lymphocytic leukemia treatment had the highest frequency of prescriptions with drug-related problems. Main drug-related problems were related to effectiveness (49.2%) and safety (33.2%), with most of them due to drug selection and dose. Rate of acceptance of interventions was 92.2% and 90.6% of drug-related problems were fully resolved. Mercaptopurine and filgrastim were the drugs most associated with drug-related problems. Oral antineoplastic agents represented 36% of the prescriptions with drug-related problems. Conclusion: The high rate of acceptance of pharmacist interventions demonstrates the relevance of the pharmacist participation in the care of hospitalized pediatric patients undergoing chemotherapy. Pharmacists need to take attention to cases of necessity of drug prescription, intervening with other health professionals. Special attention to oral chemotherapy is required.

1 May 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
LELídia Einsfeld
Lídia Einsfeld
LHLaura Caroline Tavares Hastenteufel
Laura Caroline Tavares Hastenteufel
DTDavid Taber
David Taber
NCNadine Clausell
Nadine Clausell
LGLivia Adams Goldraich
Livia Adams Goldraich
What is known and Objective Clinical pharmacists' involvement in the care of solid organ transplant recipients has been discussed worldwide given its potential to improve clinical outcomes. As thoracic transplant activity grows in Brazil, it is important to understand how pharmacists are inserted in transplant programmes nationwide. We conducted a survey to explore clinical pharmacy activities in thoracic transplant centres in Brazil and compared them with accredited programmes in the United States. Methods An electronic questionnaire was distributed to all 40 heart and lung transplant centres registered in the Brazilian Organ Transplantation Agency (ABTO) in May 2019. Survey findings were compared to previously published data from accredited U.S. centres. Results and Discussion From 22 centre respondents, ten (45.5%) declared not to have a pharmacist at any part of the transplantation process, which translated into 158 (37.6%) transplant recipients without any direct pharmaceutical care. In centres with pharmacists (n = 12), none had a full-time professional dedicated to their heart and/or lung programmes. When compared to U.S. centres, there was a significantly lower insertion of clinical pharmacist activities among Brazilian centres. What is new and Conclusion Our findings point to an unmet need related to clinical pharmacy activity within thoracic transplant programmes, especially in a developing country, and highlight a call for action in order to reach higher accredited regulatory standards regarding pharmacist-driven workforce in transplant care worldwide.

29 November 2023 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
LELidia Einsfeld
Lidia Einsfeld
DPDiogo Pilger
Diogo Pilger
CRCassiela Roman
Cassiela Roman
Heart failure (HF) is a complex clinical syndrome with high prevalence, significant morbi-mortality and is the leading cause of hospital admissions of Brazilian patients over 65 years of age. Drug therapy plays a key role in the care of HF patients, aimed to control symptoms, improve functional classification, reduce hospital readmissions and HF-related mortality rates. Despite the evidence of drug therapy proven benefits in HF, their access through the Unified Health System (Sistema Único de Saúde, SUS) remains unexplored. [...] Abstract Heart failure (HF) is a complex clinical syndrome with high prevalence, significant morbi-mortality and is the leading cause of hospital admissions of Brazilian patients over 65 years of age. Drug therapy plays a key role in the care of HF patients, aimed to control symptoms, improve functional classification, reduce hospital readmissions and HF-related mortality rates. Despite the evidence of drug therapy proven benefits in HF, their access through the Unified Health System (Sistema Único de Saúde, SUS) remains unexplored.

9 November 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
LELidia Einsfeld
Lidia Einsfeld
LGLivia Adams Goldraich
Livia Adams Goldraich
BMBruno Matte
Bruno Matte
NCNadine Clausell
Nadine Clausell
FVFelipe Homem Valle
Felipe Homem Valle

23 February 2026 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
LRLuísa Preiss Marques da Rocha
Luísa Preiss Marques da Rocha
KAKathleen Asturian
Kathleen Asturian
ICIsabel Machado Canabarro
Isabel Machado Canabarro
LELidia Einsfeld
Lidia Einsfeld
DPDiogo Pilger
Diogo Pilger
Background: Heart failure (HF) affects an estimated 64 million individuals globally. Current guideline-directed medical therapy (GDMT) comprises four cornerstone pharmacological medications proven to reduce hospitalization and/or mortality: renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). Objective: This study aimed to describe, through an exploratory analysis, access to HF drug therapy in Primary Health Care in Brazil, via the Brazilian Unified Health System (SUS). Methods: This was a descriptive, cross-sectional study based on data [...] Abstract Background: Heart failure (HF) affects an estimated 64 million individuals globally. Current guideline-directed medical therapy (GDMT) comprises four cornerstone pharmacological medications proven to reduce hospitalization and/or mortality: renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). Objective: This study aimed to describe, through an exploratory analysis, access to HF drug therapy in Primary Health Care in Brazil, via the Brazilian Unified Health System (SUS). Methods: This was a descriptive, cross-sectional study based on data

8 September 2026 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
JQJosélio Emar de Araújo Queiroz
Josélio Emar de Araújo Queiroz
FFFrancisco Álisson Paula de França
Francisco Álisson Paula de França
RLRodrigo Fonseca Lima
Rodrigo Fonseca Lima
RSRafael Santos Santana
Rafael Santos Santana
ESElivan Silva Souza
Elivan Silva Souza
LELídia Einsfeld
Lídia Einsfeld
O objetivo deste estudo foi avaliar o impacto da pandemia de COVID-19 no processo de doação e transplante no contexto global. Métodos: Foi realizado um estudo ecológico de 2017 a 2021, examinando o número de doadores e transplantes, bem como os casos e óbitos relacionados à COVID-19. A análise de regressão linear simples foi utilizada em dois blocos: entre 2017 e 2020 e entre 2017 e 2021. Foram consideradas taxas por milhão de habitantes para avaliar os impactos. Resultados: O estudo incluiu 10 países, e Portugal apresentou o impacto mais significativo na taxa de doadores efetivos, com redução de 4.463,8 (intervalo de confiança de 95% [95%CI] -5.103,2–-3.824,4), seguido por Espanha (-3.964,4; 95%CI: -5.850,2–-2.078,6), México (-3.879,3; 95%CI -4.688,6–-3.069,9) e Austrália (-309; 95%CI -565,3–-52,7), ao contrário dos Estados Unidos, que apresentaram aumento. Em termos de taxas de transplante, destacam-se Brasil, Portugal, Espanha, França, Irã e México, que apresentaram redução. Conclusão: A pandemia de COVID-19 causou impactos significativos no processo de doação e transplante em diversos países, e a caracterização desses efeitos é fundamental para a retomada das atividades.